RTCHICAGO2020
2 de Julio de 2020

PROGRAMA

19:00 – 19:05 hs. Apertura: Dr. Gustavo Ferraris (Presidente SATRO)

19:05 – 19:10 hs. Presentación de la Jornada
Directores: Dr. José Máximo Barros
Dr. Jorge Palazzo

19:10 – 19:25 hs. Módulo 1: Cáncer de Mama y Cáncer Ginecológico
Disertante: Dra. María José Girola

- Cáncer de Mama
  - Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy.
  - A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).

- Cáncer Ginecológico
  - Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

19:25 – 19:40 hs. Módulo 2: Sistema Nervioso Central, Cáncer de Cabeza y Cuello e Inmunoterapia
Disertante: Dr. Ariel Gómez Palacios

- Sistema Nervioso Central
  - Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma: JCOG1114C.
Cáncer de Cabeza y Cuello
- Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).

Inmunoterapia
- Impact of radiotherapy on risk of adverse events in patients receiving immunotherapy: A U.S. Food and Drug Administration pooled analysis.


19:50 – 20:05 hs. Módulo 3: Cáncer Genitourinario y Gastrointestinal
Disertante: Dra. Constanza Oliveri
- Cáncer Genitourinario
  - RTGO 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
- Cáncer Gastrointestinal
  - Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.
  - Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

20:05 – 20:20 hs. Módulo 4: Cáncer de Pulmón
Disertante: Dr. Federico Díaz
- Cáncer de Pulmón
  - Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC).
  - First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS).
  - Neoadjuvant Treatment with chemotherapy or chemoradiation in stage III non-small cell lung cancer: Analysis of the National Cancer Database.


20:30 – 20:35 hs. Palabras de cierre: Dra. Luisa Rafailovici